Published on 26/12/2025
Key Questions Sponsors Should Ask During CRO Evaluation
Choosing the right Contract Research Organization (CRO) is one of the most critical decisions in the clinical development process. Whether a sponsor is running a first-in-human trial or managing a global Phase III study, the CRO’s expertise, compliance, scalability, and communication model will directly influence study success. To ensure informed selection, sponsors must ask targeted, strategic questions during CRO evaluations. This article provides a comprehensive checklist of essential questions sponsors should ask to evaluate CRO capabilities, operational readiness, and cultural fit.
Why Asking the Right Questions Matters
CRO selection is not just a procurement exercise—it’s a risk mitigation strategy. Asking the right questions ensures:
- Alignment on therapeutic experience and regulatory expectations
- Transparency on operational capacity and timelines
- Understanding of compliance and audit readiness
- Clarity on communication and escalation pathways
- Confidence in vendor partnership beyond contractual obligations
Therapeutic and Operational Experience
Before initiating a project, validate the CRO’s domain expertise and delivery capabilities:
- What is your experience in the target indication or therapeutic area?
- Can you provide examples of similar trials conducted in the past 3 years?
- What were the key challenges, and how did you overcome them?
- Do you have ongoing trials in the same indication?
- How do you
Regulatory and Quality Compliance
CROs must meet regulatory expectations across jurisdictions. Ask:
- Have you undergone recent regulatory inspections (e.g., USFDA, EMA, CDSCO)? What were the outcomes?
- How is your Quality Management System (QMS) structured?
- What is your deviation, CAPA, and audit tracking system?
- How often do you update your Pharmaceutical SOP guidelines and training programs?
- How do you ensure compliance when subcontracting vendors or labs?
Global Capabilities and Site Management
For multi-regional trials, global operational infrastructure is key:
- What countries and regions do you operate in directly?
- Do you have local offices or partner CROs in these regions?
- How do you handle customs, import/export, and local regulatory submissions?
- Can you share your average site start-up timeline per region?
- How do you assess and qualify investigational sites?
Data Management and Technology
Ensure that the CRO’s data systems meet standards for quality and speed:
- Which EDC systems do you use, and are they validated?
- Do you offer in-house biostatistics and data management?
- How do you ensure data integrity and traceability?
- Can you support blinded and unblinded data workflows?
- How do you ensure secure, compliant access for sponsors?
Project Management and Communication
Project oversight and sponsor engagement directly affect quality:
- What is your project team structure for a study of this size?
- How often do you conduct project review meetings?
- What is your escalation pathway for project issues?
- Will I have direct access to therapeutic leads or medical monitors?
- What is your turnover rate for project staff?
Site Monitoring and Risk Management
- Do you follow a risk-based monitoring model?
- How do you assign CRA workloads?
- What is your CRA training and evaluation process?
- How do you track and respond to site deviations or queries?
- Do you support remote monitoring or hybrid models?
Safety and Pharmacovigilance
- Do you have an in-house safety/pharmacovigilance team?
- How do you handle expedited safety reporting to regulatory agencies?
- Do you support DSUR, SUSAR, and aggregate report preparation?
- Are your PV systems validated and audit-ready?
- How do you integrate with sponsor safety databases?
Financial Transparency and Flexibility
- Can you provide a detailed itemized budget with assumptions?
- How do you manage change orders during the trial?
- What is your approach to milestone-based billing?
- Do you support pass-through cost transparency?
- Are you open to risk-sharing or performance-based contracts?
Technology Integration and Innovation
- Do you support eConsent, ePRO, eCOA, and remote data capture?
- Can you interface with sponsor CTMS or safety systems?
- Have you worked with Stability Studies systems for sensitive investigational products?
- How do you handle protocol amendments in digital systems?
- Do you offer site training via virtual platforms?
Reference and Track Record Validation
- Can you provide sponsor references for similar studies?
- What is your average client retention rate?
- What percentage of clients engage in repeat business?
- Can you share KPIs from recently completed trials?
- Do you have a CRO scorecard you can share?
Red Flags and Final Due Diligence
- Incomplete or evasive responses to inspection history
- Lack of clear CAPA process or deviation tracking
- High CRA turnover without mitigation strategy
- No experience in the specific therapeutic area
- Reluctance to provide references or client feedback
Conclusion: Ask Strategically to Choose Wisely
Evaluating CROs with a structured question framework ensures that sponsors can identify the right partner—not just a vendor—for their clinical trial needs. From therapeutic experience to data systems, and safety to regulatory readiness, each question brings clarity on whether a CRO can deliver with quality, speed, and alignment. These insights form the foundation of a successful outsourcing strategy, supporting GCP compliance, efficient operations, and long-term collaboration.